With £11.5m recently raised to support major pipeline expansion (including the newly acquired VLP technology to develop a peanut allergy vaccine) and further small accretive deals, Allergy (AGY) is well placed for the rest of 2016. The US opportunity for the Pollinex Quattro ultra-short course range remains potentially transformational, but AGY is also targeting a greater share of the expanding EU market. Our increased DCF valuation of £274m is fair value, ahead of multiple potential catalysts over the next year.
